Thetis Pharmaceuticals Secures $4.2 Million From the Helmsley Charitable Trust to Advance Its First-in-Class Resolvin Oral Therapy for Crohn’s Disease

RIDGEFIELD, CT AND NEW YORK, NY – (April 5, 2022) – Thetis Pharmaceuticals (“Thetis”), a pioneering therapeutics biotechnology company developing a first-in-class small molecule (TP-317) as a potential oral first-line therapy for treatment of Crohn’s disease, has secured $4.2 million in non-dilutive financing from The Leona M. and Harry B. Helmsley Charitable Trust. Structured as […]

Chris Takimoto, MD, PhD, Physician-Scientist and Oncology Drug Developer, Joins Thetis Pharmaceuticals Scientific Advisory Board

RIDGEFIELD, CT – (December 2, 2021) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing immunoresolving myeloid agonists to treat cancer and autoimmune diseases, announced today that Dr. Chris Takimoto has joined its Scientific Advisory Board. Dr. Takimoto is a physician scientist with expertise in cancer drug development.  Gary Mathias, Chief Executive Officer of Thetis, […]

Sui Huang, MD, PhD, Pioneering Cancer Biology Researcher, Joins Thetis Pharmaceuticals Scientific Advisory Board

RIDGEFIELD, CT – (October 13, 2021) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing Resolvin-based therapies to treat cancer and autoimmune diseases, announced today that Dr. Sui Huang has joined its Scientific Advisory Board. Dr. Huang is a molecular and cellular biologist with expertise in systems biology of cancer progression and inflammation. Gary Mathias, […]

Thetis Pharmaceuticals Announces Patent Issuance in Japan for its Resolvin E1 candidate, TP-317, for Cancer and Autoimmune Diseases

RIDGEFIELD, CT – (August 23, 2021) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company developing Resolvin-based therapies, announced today that the Japanese Patent Office has granted patent JP 6906047 providing composition of matter protection for its lead program TP-317 (Resolvins E1 magnesium lysinate) for solid tumor cancers and inflammatory bowel disease. “TP-317 is a novel […]

Thetis Pharmaceuticals Receives Orphan Drug Designation from FDA for Resolvin E1 Therapy for Pancreatic Cancer

RIDGEFIELD, CT – (July 28, 2021) – Thetis Pharmaceuticals (“Thetis”), a leading developer of Resolvin-based therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TP-317 for treatment of pancreatic cancer. “TP-317 is a first-in-class Resolvin E1 therapy that offers a transformative new […]